Accuray Inc (ARAY)
1.755
-0.04
(-1.96%)
USD |
NASDAQ |
May 07, 16:00
1.755
0.00 (0.00%)
After-Hours: 20:00
Accuray Research and Development Expense (Quarterly): 10.91M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.91M |
| December 31, 2023 | 15.28M |
| September 30, 2023 | 14.01M |
| June 30, 2023 | 14.19M |
| March 31, 2023 | 14.21M |
| December 31, 2022 | 14.64M |
| September 30, 2022 | 14.09M |
| June 30, 2022 | 14.57M |
| March 31, 2022 | 14.10M |
| December 31, 2021 | 14.70M |
| September 30, 2021 | 14.38M |
| June 30, 2021 | 15.36M |
| March 31, 2021 | 13.27M |
| December 31, 2020 | 11.96M |
| September 30, 2020 | 12.15M |
| June 30, 2020 | 12.22M |
| March 31, 2020 | 11.16M |
| December 31, 2019 | 13.06M |
| September 30, 2019 | 13.34M |
| June 30, 2019 | 16.05M |
| March 31, 2019 | 12.91M |
| December 31, 2018 | 13.64M |
| September 30, 2018 | 13.89M |
| June 30, 2018 | 14.59M |
| March 31, 2018 | 13.91M |
| Date | Value |
|---|---|
| December 31, 2017 | 14.66M |
| September 30, 2017 | 14.09M |
| June 30, 2017 | 13.26M |
| March 31, 2017 | 12.48M |
| December 31, 2016 | 11.94M |
| September 30, 2016 | 12.23M |
| June 30, 2016 | 14.16M |
| March 31, 2016 | 13.27M |
| December 31, 2015 | 14.93M |
| September 30, 2015 | 14.30M |
| June 30, 2015 | 14.85M |
| March 31, 2015 | 12.84M |
| December 31, 2014 | 13.92M |
| September 30, 2014 | 14.15M |
| June 30, 2014 | 13.58M |
| March 31, 2014 | 13.76M |
| December 31, 2013 | 13.44M |
| September 30, 2013 | 12.95M |
| June 30, 2013 | 14.69M |
| March 31, 2013 | 15.70M |
| December 31, 2012 | 17.24M |
| September 30, 2012 | 18.57M |
| June 30, 2012 | 21.49M |
| March 31, 2012 | 22.40M |
| December 31, 2011 | 18.28M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.91M
Minimum
Mar 2024
16.05M
Maximum
Jun 2019
13.68M
Average
14.10M
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp | 366.00M |
| Integer Holdings Corp | 15.75M |
| ResMed Inc | 77.07M |
| Glaukos Corp | 30.73M |
| Perspective Therapeutics Inc | 6.08M |